New Studies on Pharmaceuticals Industry by GBI Research

06 Feb 2012 • by Natalie Aster

Antipsychotics Market to 2017 - Patent Expiries for Zyprexa, Abilify, Seroquel and Geodon and the Launch of Generic Versions Will Limit Commercial Opportunities for Pipeline Molecules. Global antipsychotics market has shown a rising trend from 2002, growing at a Compound Annual Growth Rate (CAGR) of 4.8% to reach $14 billion in 2010. Antipsychotic drugs remain the standard care for the treatment of mental disorders such as schizophrenia and bipolar disorder. The global antipsychotic market for such treatments is made up of 70% schizophrenia therapeutics and 30% bipolar disorder therapeutics.

However, the patent expiries of the leading antipsychotics such as Zyprexa, Abilify, Geodon, and Seroquel in the forecast period, followed by the immediate entry of generic versions are expected to increase price competition in the global antipsychotics market and so may limit the commercial opportunities to pipeline molecules. As a result the global antipsychotics market is expected to decline at a CAGR of 0.4% from $14 billion in 2010 to $13.8 billion in 2017.

Men's Health Therapeutics Market to 2017 - Availability of Generic Sildenafil from 2012 to Restrain Market Growth. Global men’s health market was estimated to be worth $9,162m, representing a Compound Annual Growth Rate (CAGR) of 8.4% between 2002 and 2010. By 2017, the global men’s health market is estimated to reach $12,163m, indicating a CAGR of 4.1% between 2010 and 2017. The major reason for the reduced growth rate is the first patent expiry of the blockbuster drug, Viagra (sildenafil citrate) in 2012. The drug contributes significantly to the entire men’s health market, and accounts for more than 55% of the market’s revenue. As a result, the patent expiry of this drug will directly affect the market’s growth.

Men’s health pipeline portfolio comprises both me-too and first-in-class molecules in the late stage of development. These molecules are expected to be launched during the forecast period. Some of these pipeline candidates offer improved therapeutic outcomes and a better safety profile compared to current market products. If launched, these drugs will offer physicians and patients better treatment options. This will boost the market growth. In addition, a steady increase in the diseased population and in the treated population will sustain modest market growth during the forecast period.

Price Per Report: $3.500,00 (Single User License)

More new market research reports by can be found at GBI Research page.

To order the report or ask for sample pages contact [email protected]

Contacts

MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970
[email protected]
MarketPublishers.com